- Trials with a EudraCT protocol (143)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (25)
143 result(s) found for: D2.
Displaying page 2 of 8.
EudraCT Number: 2019-002858-23 | Sponsor Protocol Number: PI2019_843_0051 | Start Date*: 2019-11-20 |
Sponsor Name:CHU Amiens-Picardie | ||
Full Title: Serratus plain block versus paravertebral block versus serratus plain block and paravertebral block for postoperative pain following thoracoscopic surgery | ||
Medical condition: postoperative pain following thoracoscopic surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000649-30 | Sponsor Protocol Number: P150905 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Impact of the administration of Fludrocortisone the fluid and electrolyte balance in great premature. Pilot study. | |||||||||||||
Medical condition: Great prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001144-36 | Sponsor Protocol Number: CHUBX2015/41 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: TRAnexamic Acid for Preventing postpartum hemorrhage following a Cesarean Delivery :a multicenter randomised, double blind placebo controlled trial (TRAAP2) | ||||||||||||||||||
Medical condition: Postpartum hemorrhage, prevention, blood loss, transfusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000207-36 | Sponsor Protocol Number: 275AS101 | Start Date*: 2020-11-18 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 ... | ||||||||||||||||||
Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020386-24 | Sponsor Protocol Number: TRO19622CLEQ1275-1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients. | |||||||||||||
Medical condition: Spinal Muscular Atrophy (type 2 or type 3 non ambulant patients aged 3-25 years) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) NL (Completed) BE (Completed) DE (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002319-41 | Sponsor Protocol Number: HULP-VIR-2014-01 | Start Date*: 2015-05-11 | |||||||||||
Sponsor Name:Ana Boto de los Bueis | |||||||||||||
Full Title: Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis. | |||||||||||||
Medical condition: Acute adenoviral conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001838-26 | Sponsor Protocol Number: THEA-LT0455-PIV-09/16 | Start Date*: 2017-07-26 | |||||||||||
Sponsor Name:THEA | |||||||||||||
Full Title: Comparison of NAABAK® efficacy versus FLUCON® in the treatment of moderate manifestations of allergic conjunctivitis to birch pollen in subjects exposed to birch in ALYATEC’s environmental exposure... | |||||||||||||
Medical condition: Subjects presenting moderate allergic conjunctivitis to birch pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003131-38 | Sponsor Protocol Number: DOPA2016 | Start Date*: 2017-06-23 |
Sponsor Name:TARGID, KU Leuven | ||
Full Title: The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study | ||
Medical condition: Increased esophageal sensitivity in refractory gastro-esophageal reflux disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019552-50 | Sponsor Protocol Number: GEXMab52101 | Start Date*: 2010-07-21 | |||||||||||
Sponsor Name:Glycotope GmbH | |||||||||||||
Full Title: Dose-escalation-, PK- and safety study with single agent CetuGEXTM in patients with EGFR positive locally advanced and/or metastatic cancer | |||||||||||||
Medical condition: Histologically confirmed locally advanced and/or metastatic solid organ tumour | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003340-11 | Sponsor Protocol Number: R076477SCH4026 | Start Date*: 2008-11-03 | |||||||||||
Sponsor Name:JANSSEN-CILAG GmbH | |||||||||||||
Full Title: The “therapeutic window” of the "atypical” antipsychotic paliperidone ER - A Positron Emission Tomography study with [18F]fallypride as the radiotracer | |||||||||||||
Medical condition: subchronic schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005406-96 | Sponsor Protocol Number: AB20006 | Start Date*: 2022-10-07 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with sev... | |||||||||||||
Medical condition: severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001209-17 | Sponsor Protocol Number: MEDI4736-MM-003 | Start Date*: 2016-09-13 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPL... | |||||||||||||
Medical condition: Relapsed and refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) DK (Completed) ES (Temporarily Halted) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002605-38 | Sponsor Protocol Number: CA224-020 | Start Date*: 2015-08-26 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Neoplasms by site | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) Outside EU/EEA IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001314-19 | Sponsor Protocol Number: VO659-CT01 | Start Date*: 2023-04-25 | ||||||||||||||||
Sponsor Name:VICO Therapeutics B.V. | ||||||||||||||||||
Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp... | ||||||||||||||||||
Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) DK (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002477-56 | Sponsor Protocol Number: IMGN632-0802 | Start Date*: 2020-01-08 | |||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||
Full Title: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia | |||||||||||||
Medical condition: CD123 positive Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001242-25 | Sponsor Protocol Number: BBT120126032001 | Start Date*: 2017-02-07 | ||||||||||||||||
Sponsor Name:Blueberry Therapeutics Ltd. | ||||||||||||||||||
Full Title: An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spr... | ||||||||||||||||||
Medical condition: Onychomycosis and associated Tinea Pedis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003953-34 | Sponsor Protocol Number: 101-001 | Start Date*: 2009-12-14 |
Sponsor Name:D2 Derma Europe Ltd. | ||
Full Title: A randomized, placebo-controlled, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region... | ||
Medical condition: Herpes simplex virus type 1 infection in the region of the mouth and the openings of the nose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005757-22 | Sponsor Protocol Number: 2005-0055757-22 | Start Date*: 2006-12-29 |
Sponsor Name:Institut de Recerca / Hospital de la Santa Creu i Sant Pau | ||
Full Title: Estudio sobre la utilidad de la Escala de Craving (EMCA), de la Escala de Deterioro del Autocontrol (EDACA) y del SPECT con yodobenzamida-I-123, como posibles predictores de la evolución del pacien... | ||
Medical condition: Ensayo clínico con un método diagnóstico, la tomografía por emisión de fotones (SPECT) con yodobenzamida-I-123 (IBZM), que permite evaluar la captación específica de IBZM por parte de los receptore... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001430-34 | Sponsor Protocol Number: 10-TT-EP-003 | Start Date*: 2012-08-14 | |||||||||||
Sponsor Name:Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: Therapeutic effectiveness, safety and tolerability of Tonsilotren tablets in patients (6 to 60 years old) with chronic tonsillitis. A randomized, international, multicenter, controlled clinical t... | |||||||||||||
Medical condition: Chronic tonsillitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000684-42 | Sponsor Protocol Number: 2008 09 | Start Date*: 2009-01-13 |
Sponsor Name:Assistance Publique Hopitaux de marseille | ||
Full Title: ETUDE PILOTE POUR L’EVALUATION DE LA FAISABILITE ET LA VALIDATION D’UN PROTOCOLE SCINTIGRAPHIE DES RECEPTEURS DOPAMINERGIQUES (123I-IBZM) DANS LES PHEOCHROMOCYTOMES ET PARAGANGLIOMES | ||
Medical condition: TUMEURS ISSUES DU TISSU CHROMAFFINE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
